• Gabriela Steiner, Leslie W Suen, Marlene Martin, Sasha Skinner, Pierre Crouch, Oanh K Nguyen, Kristin Slown, and Alexander Logan.
• University of California, San Francisco, 1001 Potrero Avenue, Bldg 5 Rm 5H06, San Francisco, CA, 94110, USA.
• J Gen Intern Med. 2025 Jan 6.

BackgroundFentanyl use leads to increased opioid tolerance in people with opioid use disorder, complicating management of opioid withdrawal syndrome. While accepted as gold standard, methadone and buprenorphine may be insufficient to treat acute opioid withdrawal. Short-acting full agonist opioids (SAFAO) may improve treatment in the acute care setting.AimCharacterize use of SAFAO to treat opioid withdrawal syndrome for inpatients.SettingUrban safety-net hospital.ParticipantsInpatients with opioid use disorder.Program DescriptionAddiction Consult Team offers SAFAO to manage opioid withdrawal syndrome.Program EvaluationWe performed retrospective chart review of hospitalizations (n = 124) for patients with opioid use disorder who received SAFAO between March and June 2023. Patients received methadone or buprenorphine during 94% of hospitalizations. On average, 278 mg (SD 407 mg) oral morphine equivalents (OMEs) of SAFAO were administered daily during the first hospitalization week. Daily Clinical Opiate Withdrawal Scale scores and SAFAO OMEs were inversely correlated (Spearman rank correlation = - 0.96, p = 0.003). Five hospitalizations exhibited adverse events (AEs).DiscussionUse of methadone/buprenorphine did not alleviate the need for SAFAO, suggesting that SAFAO administration may be an important intervention for opioid withdrawal. Use of escalating OMEs of SAFAO was associated with reduced withdrawal severity. This practice was well-tolerated with few AEs.© 2025. The Author(s).

4 keywords...

hide…